Naonori Kawakubo

Dr. Naonori Kawakubo

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AAAyumu Arakawa
Ayumu Arakawa
HIHitoshi Ichikawa
Hitoshi Ichikawa
TKTakashi Kubo
Takashi Kubo
NMNoriko Motoi
Noriko Motoi
TKTadashi Kumamoto
Tadashi Kumamoto
COChitose Ogawa
Chitose Ogawa
Two cases of pediatric lung cancer (in 23-month-old and 6-year-old boys) resulting from mother-to-infant transmission of uterine cervical tumors were incidentally detected during routine next-generation sequencing of paired samples of tumor and normal tissue. Spontaneous regression of some lesions in the first child and slow growth of the tumor mass in the second child suggested the existence of alloimmune responses against the transmitted tumors. Immune checkpoint inhibitor therapy with nivolumab led to a strong regression of all remaining tumors in the first child. (Funded by the Japan Agency for Medical Research and Development and others; TOP-GEAR UMIN Clinical Trials Registry number, UMIN000011141.)

1 April 2019 in Journal of Surgical Research
Verified
Journal Article
Closed access
NKNaonori Kawakubo
Naonori Kawakubo
YKYoshiaki Kinoshita
Yoshiaki Kinoshita
RSRyota Souzaki
Ryota Souzaki
YKYuhki Koga
Yuhki Koga
UOUtako Oba
Utako Oba
TTTomoaki Taguchi
Tomoaki Taguchi

5 September 2023 in Surgery Today
Verified
Journal Article
Closed access
PDF file
KYKoichiro Yoshimaru
Koichiro Yoshimaru
TMToshiharu Matsuura
Toshiharu Matsuura
YUYasuyuki Uchida
Yasuyuki Uchida
SSSoichiro Sonoda
Soichiro Sonoda
SMShohei Maeda
Shohei Maeda
TTTatsuro Tajiri
Tatsuro Tajiri

1 January 2025 in Pediatrics International
Verified
Journal Article
Open access
MOMichio Ozeki
Michio Ozeki
SESaori Endo
Saori Endo
SYShiho Yasue
Shiho Yasue
RARyuta Asada
Ryuta Asada
ASAkiko M. Saito
Akiko M. Saito
AFAkihiro Fujino
Akihiro Fujino
Background: Intractable vascular anomalies (VAs), including vascular tumors and venous, lymphatic, and mixed malformations, often have severe symptoms and a poor prognosis, highlighting the need for new treatments. We conducted a prospective trial of sirolimus (tablet and granule forms) for the treatment of VAs. Methods: In this open‐label, single‐arm, multicenter trial across four Japanese institutions, patients with VAs received oral sirolimus daily, targeting a trough concentration of 5–15 ng/mL. We evaluated response rates (radiological volume changes in lesions), skin lesions, performance status, respiratory function, visceral symptoms (bleeding, pain), laboratory data, quality of life, and safety at 12, 24, and 52 weeks. Results: Thirteen patients with VAs were treated with sirolimus. Seven patients (53.8%; 95% confidence interval: 25.1%–80.8%) showed a partial radiological response at 24 weeks, with no complete responses, and 61.5% had a partial response by 12 weeks, with little subsequent change in patients who had stable disease thereafter. Improvements in skin lesions, blood coagulation, and activities of daily living were noted. Common adverse events included stomatitis, dermatitis, diarrhea, and fever. Conclusions: Sirolimus may reduce VA tissue volume and potentially improve symptoms and activities of daily living in patients with VAs.

28 September 2022 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
AOAtsuko Omori
Atsuko Omori
NKNaonori Kawakubo
Naonori Kawakubo
JTJunkichi Takemoto
Junkichi Takemoto
RSRyota Souzaki
Ryota Souzaki
SOSatoshi Obata
Satoshi Obata
TTTomoaki Taguchi
Tomoaki Taguchi

Verified
Journal Article
Open access
PDF file
VTVlad Tocan
Vlad Tocan
AUAkari Utsunomiya
Akari Utsunomiya
YSYuri Sonoda
Yuri Sonoda
WMWakato Matsuoka
Wakato Matsuoka
SMSoichi Mizuguchi
Soichi Mizuguchi
SOShouichi Ohga
Shouichi Ohga
Severe obesity in young children prompts for a differential diagnosis that includes syndromic conditions. Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) syndrome is a potentially fatal disorder characterized by rapid-onset obesity associated with hypoventilation, neural crest tumors, and endocrine and behavioral abnormalities. The etiology of ROHHAD syndrome remains to be established, but recent research has been focusing on autoimmunity. We report on a 2-year-old girl with rapid-onset obesity during the first year of life who progressed to hypoventilation and encephalitis in less than four months since the start of accelerated weight gain. The patient had a high titer of anti-ZSCAN1 antibodies (348; reference range < 40), and the increased values did not decline after acute phase treatment. Other encephalitis-related antibodies, such as the anti-NDMA antibody, were not detected. The rapid progression from obesity onset to central hypoventilation with encephalitis warns about the severe consequences of early-onset ROHHAD syndrome. These data indicate that serial measurements of anti-ZSCAN1 antibodies might be useful for the diagnosis and estimation of disease severity. Further research is needed to determine whether it can predict the clinical course of ROHHAD syndrome and whether there is any difference in antibody production between patients with and without tumors.